SCHEMBL3215094

SCHEMBL3215094

O=C(O)C=Cc1ccc(NCCOc2ccc(F)cc2)nc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GCK P35557 1/20 0.45
HDAC1 Q13547 2/20 0.44
TBXAS1 P24557 2/20 0.44
P4HTM Q9NXG6 1/20 0.44
GSK3B P49841 2/20 0.43
BACE1 P56817 2/20 0.43
MAOB P27338 2/20 0.43
POLB P06746 1/20 0.42
HCAR3 P49019 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR7 P34969 1/20 0.41
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3215078 1.00 MEN1 (0.52) MEN1KMT2AMAPTHTTNPSR1
SCHEMBL8189106 0.88 KMT2A (0.54) MEN1KMT2AMAPTHTTNPSR1
SCHEMBL3225261 0.82 ALDH1A1 (0.54) MEN1KMT2AMAPTHTTNPSR1
SCHEMBL13428582 0.80 KMT2A (0.48) MEN1KMT2AMAPTHTTNPSR1
SCHEMBL8179174 0.80 KMT2A (0.48) MEN1KMT2AMAPTHTTNPSR1
SCHEMBL1062818 0.77 HDAC1 (0.67) GCKHDAC1P4HTMRAB9ASMN1; SMN2
SCHEMBL1062815 0.77 HDAC1 (0.67) GCKHDAC1P4HTMRAB9ASMN1; SMN2
SCHEMBL18712338 0.77 HCAR3 (0.60) GCKHDAC1P4HTMHCAR3RAB9A
SCHEMBL3618167 0.75 ALDH1A1 (0.65) MEN1KMT2AP4HTMGSK3BBACE1
SCHEMBL3232430 0.75 HTR7 (0.46) MEN1KMT2ASMN1; SMN2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069388-A1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2010-03-18 US disclosed
EP-2099756-A1 N-HYDROXYACRYLAMIDE COMPOUNDS Astellas Pharma Inc. (JP) 2009-09-16 EP disclosed
WO-2008075757-A1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069388-A1 N-HYDROXYACRYLAMIDE COMPOUNDS HDAC1, HDAC11, HDAC2 MEN1 2025/4885KMT2A 31/4885MAPT 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.